Clinical trial results:
A Randomized Study Comparing Maintenance Therapy with Subcutaneous Rituximab Continued Until Progression with Observation Only in Patients with Relapsed or Refractory, Indolent Non-Hodgkin's Lymphoma who Completed and Responded to Rituximab-based Immunochemotherapy Induction and Initial 2-year Rituximab Maintenance Therapy Administered Subcutaneously

Summary

EudraCT number	2010-023407-95
Trial protocol	GB DE SE AT SK LT HU FR ES SI IT GR
Global end of trial date	02 June 2018

Results information

Result version number	v1 (current)
This version publication date	16 June 2019
First version publication date	16 June 2019

Trial information

Trial identification

Sponsor protocol code	MO25455

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01461928
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, globa.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, globa.trial_information@roche.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 June 2018
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	02 June 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the trial was to evaluate the efficacy of a subcutaneous (SC) formulation of rituximab in terms of progression-free survival after randomization (PFSrand) to either prolonged rituximab maintenance until progression (Maintenance II) or observation in subjects with relapsed or refractory, indolent non-Hodgkin's lymphoma who responded to Induction and initial 2 years maintenance therapy (Maintenance I) at the end of study (EOS).

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 December 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Albania: 18
Country: Number of subjects enrolled	Argentina: 6
Country: Number of subjects enrolled	Austria: 8
Country: Number of subjects enrolled	Brazil: 50
Country: Number of subjects enrolled	Bulgaria: 12
Country: Number of subjects enrolled	Colombia: 6
Country: Number of subjects enrolled	Ecuador: 6
Country: Number of subjects enrolled	Egypt: 11
Country: Number of subjects enrolled	France: 128
Country: Number of subjects enrolled	Germany: 33
Country: Number of subjects enrolled	Greece: 24
Country: Number of subjects enrolled	Hungary: 28
Country: Number of subjects enrolled	Italy: 115
Country: Number of subjects enrolled	Lithuania: 2
Country: Number of subjects enrolled	Norway: 18
Country: Number of subjects enrolled	Romania: 13
Country: Number of subjects enrolled	Russian Federation: 39
Country: Number of subjects enrolled	Slovakia: 2
Country: Number of subjects enrolled	Slovenia: 2

Country: Number of subjects enrolled	Spain: 61
Country: Number of subjects enrolled	Sweden: 10
Country: Number of subjects enrolled	Turkey: 9
Country: Number of subjects enrolled	United Kingdom: 90
Country: Number of subjects enrolled	Switzerland: 1
Worldwide total number of subjects	692
EEA total number of subjects	546

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	322
From 65 to 84 years	355
85 years and over	15

Subject disposition

Recruitment

Recruitment details:

Subjects were identified for potential recruitment using pre-screening enrolment logs.

Pre-assignment

Screening details:

Subjects were treated with an induction regimen (6 months) and received SC rituximab at a dose of 375 mg/m2 with chemotherapy followed by 2 years of Maintenance I SC rituximab of 1400 mg alone. Responding subjects at the end of Maintenance I were randomised to either Maintenance II rituximab treatment or observation only.

Pre-assignment period milestones

Number of subjects started	692
Intermediate milestone: Number of subjects	Maintenance I: 494
Number of subjects completed	276

Pre-assignment subject non-completion reasons

Reason: Number of subjects	Adverse Event (AE): 146
Reason: Number of subjects	Disease progression: 136
Reason: Number of subjects	Lost to follow-up: 7
Reason: Number of subjects	Physician decision: 18
Reason: Number of subjects	Consent withdrawn by subject: 50
Reason: Number of subjects	Eligibility criteria deviation: 10
Reason: Number of subjects	Completed Induction, no Maint I received: 11
Reason: Number of subjects	Not responding to treatment: 11
Reason: Number of subjects	Termination of study in Switzerland: 1
Reason: Number of subjects	Treated before eligibility was confirmed: 1
Reason: Number of subjects	Sponsor decision: 1
Reason: Number of subjects	Protocol deviation: 2
Reason: Number of subjects	Prednisolone given prior to enrolment: 1
Reason: Number of subjects	Cycle 7 rituximab not given in error: 1
Reason: Number of subjects	Promotor request: 1
Reason: Number of subjects	Exceeded time limit for next cycle: 1
Reason: Number of subjects	Medical advisor request: 1
Reason: Number of subjects	Did not meet randomization criteria: 2
Reason: Number of subjects	Did not perform scheduled assessment: 2
Reason: Number of subjects	Delay in rituximab administration: 1
Reason: Number of subjects	Death: 6
Reason: Number of subjects	Not compliant: 1
Reason: Number of subjects	Did not meet criteria: 5

Period 1

Period 1 title	Maintenance II (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm A

Arm description:

Subjects received SC rituximab administered as a single injection of 1400 mg fixed dose without chemotherapy every 8 weeks until disease progression or until the end of study.

Arm type	Experimental
Investigational medicinal product name	rituximab
Investigational medicinal product code	
Other name	Mabthera
Pharmaceutical forms	Solution for injection/infusion in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

A single dose of subcutaneous injection at a dose of 1400 mg without chemotherapy administered every 8 weeks

Arm title	Arm B (Observation only)

Arm description:

Subjects did not receive further rituximab treatment until the end of study.

Arm type	No intervention

No investigational medicinal product assigned in this arm

Number of subjects in period 1[1]	Arm A	Arm B (Observation only)
Started	138	138
Completed	115	111
Not completed	23	27
Moved to another town	1	-
Consent withdrawn by subject	9	8
Physician decision	-	4
Disease progression	-	3
Changed physician in another hospital	-	1
Withdrew informed consent	-	1
Death	10	8
Squamous lung carcinoma	-	1
Adverse event	2	-
Refused to be transferred to other site	-	1
Lost to follow-up	1	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The main reporting group included randomised subjects who were a subset of the overall worldwide enrollment.

Baseline characteristics

Reporting groups	
Reporting group title	Arm A
Reporting group description:	
Subjects received SC rituximab administered as a single injection of 1400 mg fixed dose without chemotherapy every 8 weeks until disease progression or until the end of study.	
Reporting group title	Arm B (Observation only)
Reporting group description:	
Subjects did not receive further rituximab treatment until the end of study.	

Reporting group values	Arm A	Arm B (Observation only)	Total
Number of subjects	138	138	276
Age Categorical Units: Subjects			
Adults (18-64 years)	76	68	144
From 65-84 years	60	69	129
Elderly 85 years and over	2	1	3
Age Continuous Units: years			
arithmetic mean	62.2	63.7	
standard deviation	± 10.33	± 10.93	-
Gender Categorical Units: Subjects			
Female	64	70	134
Male	74	68	142

End points

End points reporting groups

Reporting group title	Arm A

Reporting group description:

Subjects received SC rituximab administered as a single injection of 1400 mg fixed dose without chemotherapy every 8 weeks until disease progression or until the end of study.

Reporting group title	Arm B (Observation only)

Reporting group description:

Subjects did not receive further rituximab treatment until the end of study.

Subject analysis set title	Intent-to-Treat (ITT)
Subject analysis set type	Intention-to-treat

Subject analysis set description:

The ITT population included all subjects who had completed a Baseline visit and at least one on-treatment assessment. The ITT population was used for the analysis of secondary efficacy parameters and Baseline variables. All subjects who were enrolled into the given study period and had received at least one dose of study treatment at any time were included in the ITT population for each period of the study; Induction, Maintenance I and Maintenance II.

Subject analysis set title	Maintenance I Subjects
Subject analysis set type	Sub-group analysis

Subject analysis set description:

The Maintenance I subject analysis group consisted of a subgroup of responding subjects who completed Induction and successfully enrolled into Maintenance I.

Subject analysis set title	Randomised Intent-to-Treat
Subject analysis set type	Sub-group analysis

Subject analysis set description:

The primary efficacy analysis population was the ITT population (ITTrand), which included only randomised subjects (Maintenance II only) and was used for the analysis of the primary efficacy endpoint of PFS and the secondary analysis endpoint overall survival (OS).

Subject analysis set title	Safety Population (All study periods)
Subject analysis set type	Safety analysis

Subject analysis set description:

The SAF population included all subjects who had received at least one dose of rituximab during the study and were assigned to treatment groups as treated. All safety analyses were based on the SAF. All subjects were included in the SAF population for each period of the study; Induction, Maintenance I and Maintenance II.

Subject analysis set title	Per Protocol Population
Subject analysis set type	Per protocol

Subject analysis set description:

A PP analysis (PPrand) was performed with Maintenance II subjects from the ITTrand population who had no major protocol violations that may have impacted the primary analysis.

Primary: Maintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

End point title	Maintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

End point description:

Progression free survival from randomization (PFSrand) is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. The primary efficacy analysis population was the ITT population (ITTrand), which included only randomised subjects (Maintenance II only) and was used for the analysis of the primary efficacy endpoint of PFS and the secondary analysis endpoint overall survival (OS). The Observation arm did not include one subject with AE outcome of death reported retrospectively 2 months after discontinuation from study (censored as having no event on Day 456 post-randomisation). The end point was not reached. 9999=not

estimable

End point type	Primary

End point timeframe:

From randomization (Maintenance II) up to disease progression or death, whichever occurs first

End point values	Arm A	Arm B (Observation only)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	138	138[1]		
Units: Month				
median (confidence interval 95%)	9999 (9999 to 9999)	9999 (39.75 to 9999)		

Notes:

[1] - 2 subjects died due to an SAE and were not considered in the analysis as no death page was completed

Statistical analyses

Statistical analysis title	Stratified log-rank test

Statistical analysis description:

The stratified log rank test p-value was derived using the following randomization stratification strata : Follicular Lymphoma International Prognostic Index (FLIPI) risk category (low, intermediate, high) and indolent NHL subtype (follicular lymphoma, non-follicular lymphoma).

Comparison groups	Arm B (Observation only) v Arm A
Number of subjects included in analysis	276
Analysis specification	Pre-specified
Analysis type	superiority[2]
P-value	= 0.41 [3]
Method	Stratified Long-rank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	1.53

Notes:

[2] - Power at time of final analysis was less than 40%. Final analysis was not able to address it's primary objective.
[3] - Power at time of final analysis was less than 40%. Final analysis was not able to address it's primary objective.

Secondary: Number of Subjects with Adverse Events (AEs), Serious AEs, and Infusion/Administration-related Reactions (IRRs/ARRs)

End point title	Number of Subjects with Adverse Events (AEs), Serious AEs, and Infusion/Administration-related Reactions (IRRs/ARRs)

End point description:

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. The safety population included all subjects

who received at least one dose of study drug and had a safety assessment performed post randomisation. Not all AEs were followed up for the randomised Observation arm. Only Serious AEs and AE grade 3-5 (obtained retrospectively) were collected for this arm. Therefore arms are not comparable overall.

End point type	Secondary

End point timeframe:

From day of first rituximab induction dose up to day of disease progression, or discontinuation of treatment for any reason (up to approximately 87 months)

End point values	Safety Population (All study periods)			
Subject group type	Subject analysis set			
Number of subjects analysed	692			
Units: Subjects				
number (not applicable)				
Number of Subjects with Adverse Events	643			
Number of Subjects with Serious Adverse Events	339			
Number of Subjects with IRRs/ARRs	330			

Statistical analyses

No statistical analyses for this end point

Secondary: Event-free Survival (Time to Treatment Failure) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

End point title	Event-free Survival (Time to Treatment Failure) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia[4]

End point description:

The analysis population was the randomised ITT population (ITTrand), which included only randomised subjects (Maintenance II only) as well as the ITT population, that included all subjects who had completed a Baseline visit and at least one on-treatment assessment. The ITT population included all subjects who had completed a Baseline visit and at least one on-treatment assessment. All subjects who were enrolled into the given study period and had received at least one dose of study treatment at any time were included in the ITT population for each period of the study; Induction, Maintenance I and Maintenance II. 9999=not estimable

End point type	Secondary

End point timeframe:

From day of first rituximab induction dose up to day of any treatment failure, including disease progression, or discontinuation of treatment for any reason (up to approximately 87 months)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data for this endpoint was provided only for those arms which were planned to be reported.

End point values	Arm A	Intent-to-Treat (ITT)		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	138[5]	692[6]		
Units: Months				
median (confidence interval 95%)	65.38 (60.98 to 9999)	24.99 (20.73 to 27.99)		

Notes:

[5] - Treatment discontinuation was considered as an event, not applicable to observation arm.

[6] - Biased as treatment discontinuation was considered as an event, not applicable to observation arm.

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Next Lymphoma Treatment (TNLT)

End point title	Time to Next Lymphoma Treatment (TNLT)

End point description:

Time to next lymphoma treatment (TNLT) is defined as the time from date of first rituximab induction dose to the date date of first documented intake of any new antilymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc.). The analysis population was the randomised ITT population (ITTrand), which included only randomised subjects (Maintenance II only) as well as the ITT population, that included all subjects who had completed a Baseline visit and at least one on-treatment assessment. The ITT population included all subjects who had completed a Baseline visit and at least one on-treatment assessment. All subjects who were enrolled into the given study period and had received at least one dose of study treatment at any time were included in the ITT population for each period of the study; Induction, Maintenance I and Maintenance II. The end point was not reached. 9999=not estimable

End point type	Secondary

End point timeframe:

From day of first rituximab induction dose up to any new lymphoma treatment (up to approximately 87 months)

End point values	Arm A	Arm B (Observation only)	Intent-to-Treat (ITT)	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	138	138[7]	692	
Units: Months				
median (confidence interval 95%)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	

Notes:

[7] - Biased as subjects stopped treatment and were likely to receive NLT earlier.

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)

End point description:

Overall survival from first induction treatment (OSRegist) is defined as the time from date of first rituximab induction dose to the date of death, irrespective of cause The ITT population included all

subjects who had completed a Baseline visit and at least one on-treatment assessment. All subjects who were enrolled into the given study period and had received at least one dose of study treatment at any time were included in the ITT population for each period of the study; Induction, Maintenance I and Maintenance II. One subject died in Induction before randomization and one subject died in Maintenance II Observation arm due to an SAE and was not considered in the analysis as no death page was completed. The Observation arm did not include one subject with AE outcome of death reported retrospectively 2 months after discontinuation from study (censored as having no event on Day 456 post-randomisation). The end point was not reached. 9999= not estimable

End point type	Secondary

End point timeframe:

From day of first rituximab induction dose up to death (up to approximately 87 months)

End point values	Intent-to-Treat (ITT)			
Subject group type	Subject analysis set			
Number of subjects analysed	692[8]			
Units: Months				
median (confidence interval 95%)	9999 (9999 to 9999)			

Notes:

[8] - Randomised arms pooled as it includes information prior to randomisation. Interpret with caution.

Statistical analyses

No statistical analyses for this end point

Secondary: Maintenance II: Overall Survival

End point title	Maintenance II: Overall Survival

End point description:

Overall survival from randomization (OSrand) is defined as the time from date of randomization to the date of death, irrespective of cause. The analysis population was the randomised ITT population (ITTrand), which included only randomised subjects (Maintenance II only) and was used for the analysis of the primary efficacy endpoint of PFS and the secondary analysis endpoint overall survival (OS). The end point was not reached. 9999=not estimable

End point type	Secondary

End point timeframe:

From randomization (Maintenance II) up to death (up to approximately 24 months)

End point values	Arm A	Arm B (Observation only)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	138	138		
Units: Months				
median (confidence interval 95%)	9999 (9999 to 9999)	9999 (9999 to 9999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Partial Response (PR) or Complete Response (CR) Tumor response assessment at end of Induction Using 1999 International Working Group Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

End point title	Percentage of Subjects with Partial Response (PR) or Complete Response (CR) Tumor response assessment at end of Induction Using 1999 International Working Group Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

End point description:

The ITT population included all subjects who had completed a Baseline visit and at least one on-treatment assessment.

End point type	Secondary

End point timeframe:

From day of first rituximab induction dose up to end of induction period (up to approximately 8 months)

End point values	Intent-to-Treat (ITT)			
Subject group type	Subject analysis set			
Number of subjects analysed	692			
Units: Percentage				
number (confidence interval 95%)	84.7 (81.8 to 87.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Maintenance I: Percentage of Subjects with Conversion of PR to CR Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

End point title	Maintenance I: Percentage of Subjects with Conversion of PR to CR Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

End point description:

The Maintenance I subject analysis group consisted of a subgroup of responding subjects who completed Induction and successfully enrolled into Maintenance I. Subjects who had partial response (PR) at the end of Induction were included in this analysis.

End point type	Secondary

End point timeframe:

From day of first rituximab induction dose up to end of Maintenance I period (up to approximately 32 months)

End point values	Maintenance I Subjects			
Subject group type	Subject analysis set			
Number of subjects analysed	357			
Units: Number				
number (confidence interval 95%)	21.6 (17.4 to 26.2)			

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

End point title	Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia

End point description:

Progression free survival from first induction treatment (PFSregist) is defined as the time from date of first rituximab induction dose to the date of first documented disease progression or death by any cause, whichever occurs first. The ITT population included all subjects who had completed a Baseline visit and at least one on-treatment assessment. All subjects who were enrolled into the given study period and had received at least one dose of study treatment at any time were included in the ITT population for each period of the study; Induction, Maintenance I and Maintenance II.

End point type	Secondary

End point timeframe:

From day of first rituximab induction dose up to disease progression or death, whichever occurs first (up to approximately 87 months)

End point values	Intent-to-Treat (ITT)			
Subject group type	Subject analysis set			
Number of subjects analysed	692			
Units: Months				
median (confidence interval 95%)	59.33 (50.33 to 71.36)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From Baseline up to 87 months

Adverse event reporting additional description:

The SAF population included all subjects who had received at least one dose of rituximab during the study (Induction, Maint I, Maint II) and were assigned to treatment groups. Not all AEs were followed up for the randomised Observation arm. Only Serious AEs and AE grade 3-5 were collected for this arm, therefore arms are not comparable overall.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	20.1

Reporting groups

Reporting group title	Arm A

Reporting group description:

Subjects received SC rituximab administered as a single injection of 1400 mg fixed dose without chemotherapy every 8 weeks until disease progression or until the end of study.

Reporting group title	All Subjects

Reporting group description:

Subjects were enrolled in an Induction period (up to 8 months) and received SC rituximab at a dose of 375 mg/m2 body surface area (BSA) followed by standard chemotherapy then continued into Maintenance I period (up to 24 months) and received SC rituximab of 1400 mg without chemotherapy. Subjects who completed the Induction and Maintenance I periods with SC rituximab and for whom Partial Response (PR) or Complete Response (CR) was confirmed, were considered responders and were then randomised to receive either prolonged SC rituximab continued until disease progression or until the end of study (Maintenance II; Rituximab arm) or observation with no further treatment until the end of study (Maintenance II; Observation arm).

Reporting group title	Arm B (Observation only)

Reporting group description:

Subjects did not receive further rituximab treatment until the end of study.

Serious adverse events	Arm A	All Subjects	Arm B (Observation only)
Total subjects affected by serious adverse events			
subjects affected / exposed	59 / 138 (42.75%)	339 / 692 (48.99%)	58 / 138 (42.03%)
number of deaths (all causes)	10	161	8
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Transitional cell carcinoma			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			

subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences causally related to treatment / all	0 / 1	0 / 7	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of lung			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestine adenocarcinoma			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Refractory Anaemia With An Excess Of Blasts			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Rectal cancer			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Prostatic adenoma			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	2 / 138 (1.45%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Nodal Marginal Zone B-Cell Lymphoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine tumour			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Naevoid melanoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myeloid leukaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Myelodysplastic syndrome			
subjects affected / exposed	1 / 138 (0.72%)	9 / 692 (1.30%)	2 / 138 (1.45%)
occurrences causally related to treatment / all	0 / 1	0 / 9	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 3	0 / 0
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Malignant melanoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Lung adenocarcinoma			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lentigo maligna			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large cell lung cancer			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Invasive ductal breast carcinoma			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	1 / 1	1 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's disease			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular Carcinoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colorectal cancer			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Carcinoid tumour of the stomach			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bowen's disease			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaplastic astrocytoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Anal squamous cell carcinoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma pancreas			

subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myeloid leukaemia			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 4	0 / 1
Surgical and medical procedures			
Venous thrombosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vena cava thrombosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jugular vein thrombosis			

subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic vasculitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flushing			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia repair			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Sudden death			

subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Pyrexia			
subjects affected / exposed	1 / 138 (0.72%)	11 / 692 (1.59%)	3 / 138 (2.17%)
occurrences causally related to treatment / all	0 / 1	5 / 16	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injection site reaction			
subjects affected / exposed	0 / 138 (0.00%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	5 / 5	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injection site pain			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injection site induration			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injection site haematoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injection site erythema			

subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	2 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion site erythema			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	5 / 5	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammation			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 138 (0.00%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Feeling hot			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Face oedema			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 3	0 / 0
Chills			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	4 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			

subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 1	1 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Immunosupression			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			
subjects affected / exposed	2 / 138 (1.45%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	2 / 2	5 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	1 / 1	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Menometrorrhagia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Throat irritation			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	2 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			

subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pleural effusion			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal pain			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung disorder			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Haemoptysis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 138 (0.72%)	6 / 692 (0.87%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	2 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			

subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	2 / 5	2 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiectasis			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Acute pulmonary oedema			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Neutrophil count decreased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphocyte count decreased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Upper limb fracture			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth avulsion			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Spinal compression fracture			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pubis fracture			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infusion related reaction			
subjects affected / exposed	3 / 138 (2.17%)	7 / 692 (1.01%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	3 / 3	7 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Femur fracture			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	2 / 138 (1.45%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	2 / 138 (1.45%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complications of bone marrow transplant			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Chest injury			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			

subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anastomotic leak			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Atrial septal defect			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Ventricular tachycardia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Myocardial ischaemia			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congestive cardiomyopathy			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiopulmonary failure			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 1
Cardiac failure congestive			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure acute			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Cardiac failure			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardic arrest			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atrial fibrillation			
subjects affected / exposed	2 / 138 (1.45%)	7 / 692 (1.01%)	2 / 138 (1.45%)
occurrences causally related to treatment / all	0 / 2	1 / 7	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve incompetence			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve calcification			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			

subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Acute coronary syndrome			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Transient ischaemic attack			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiplegic migraine			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			

subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cognitive disorder			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular disorder			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 2	0 / 0
Cerebral atrophy			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery stenosis			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	0 / 138 (0.00%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	2 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	1 / 138 (0.72%)	22 / 692 (3.18%)	6 / 138 (4.35%)
occurrences causally related to treatment / all	0 / 1	22 / 29	10 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphopenia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	2 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperviscosity syndrome			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile Neutropenia			
subjects affected / exposed	4 / 138 (2.90%)	36 / 692 (5.20%)	2 / 138 (1.45%)
occurrences causally related to treatment / all	3 / 5	28 / 42	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone marrow failure			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Anaemia			

subjects affected / exposed	0 / 138 (0.00%)	8 / 692 (1.16%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	2 / 10	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo positional			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	1 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Dacryostenosis acquired			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haematoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pancreatitis acute			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal pseudo-obstruction			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammatory bowel disease			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal toxicity			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspepsia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticular perporation			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 138 (0.72%)	10 / 692 (1.45%)	2 / 138 (1.45%)
occurrences causally related to treatment / all	1 / 1	4 / 12	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Colitis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	1 / 2	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Liver disorder			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic steatosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis acute			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct stone			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	2 / 138 (1.45%)
occurrences causally related to treatment / all	0 / 0	2 / 2	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic skin eruption			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin reaction			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash papular			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 138 (0.00%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	4 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pruritus			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peau D'orange			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	3 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Urethral haemorrhage			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 138 (0.00%)	6 / 692 (0.87%)	3 / 138 (2.17%)
occurrences causally related to treatment / all	0 / 0	0 / 6	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Endocrine disorders			
Thyrotxic crisis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Goitre			

subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Spinal osteoarthritis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal column stenosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporotic fracture			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemarthrosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Compartment syndrome			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	14 / 138 (10.14%)	54 / 692 (7.80%)	6 / 138 (4.35%)
occurrences causally related to treatment / all	6 / 14	22 / 65	1 / 7
deaths causally related to treatment / all	0 / 0	1 / 9	0 / 1
Sepsis			
subjects affected / exposed	3 / 138 (2.17%)	18 / 692 (2.60%)	2 / 138 (1.45%)
occurrences causally related to treatment / all	0 / 3	7 / 18	1 / 2
deaths causally related to treatment / all	0 / 0	5 / 9	0 / 0
Viral upper respiratory tract infection			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 1	1 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	2 / 2	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Urinary tract infection			
subjects affected / exposed	3 / 138 (2.17%)	12 / 692 (1.73%)	2 / 138 (1.45%)
occurrences causally related to treatment / all	1 / 4	2 / 13	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 138 (0.00%)	8 / 692 (1.16%)	3 / 138 (2.17%)
occurrences causally related to treatment / all	0 / 0	5 / 9	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Tracheobronchitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 138 (0.72%)	6 / 692 (0.87%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 1	1 / 6	0 / 1
deaths causally related to treatment / all	0 / 1	1 / 3	0 / 0
Sepsis syndrome			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonellosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 138 (0.72%)	9 / 692 (1.30%)	2 / 138 (1.45%)
occurrences causally related to treatment / all	0 / 1	3 / 9	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis chronic			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary sepsis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Pseudomonas infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Progressive multifocal leukoencephalopathy			

subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	3 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Pneumocystis Jirovecii pneumonia			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Pneumococcal infection			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perineal cellulitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraspinal abscess			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Neutropenic sepsis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrotising fasciitis			

subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis septic			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Myocarditis infectious			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Meningitis aseptic			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	2 / 138 (1.45%)	7 / 692 (1.01%)	4 / 138 (2.90%)
occurrences causally related to treatment / all	2 / 2	4 / 7	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	1 / 138 (0.72%)	10 / 692 (1.45%)	5 / 138 (3.62%)
occurrences causally related to treatment / all	1 / 1	5 / 11	3 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney infection			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal sepsis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	1 / 2	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	1 / 1	2 / 5	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis viral			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Hepatitis C			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic candidiasis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemophilus infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 1	1 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterobacter sepsis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Device related sepsis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Candida infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Campylobacter gastroenteritis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 138 (0.00%)	5 / 692 (0.72%)	4 / 138 (2.90%)
occurrences causally related to treatment / all	0 / 0	1 / 5	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			

subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Metabolism and nutrition disorders			
Tumour lysis syndrome			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Hypophosphataemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Arm A	All Subjects	Arm B (Observation only)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	133 / 138 (96.38%)	643 / 692 (92.92%)	133 / 138 (96.38%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	5 / 138 (3.62%)	17 / 692 (2.46%)	5 / 138 (3.62%)
occurrences (all)	5	19	5
Bowen's disease			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	2 / 138 (1.45%)
occurrences (all)	0	3	2
Squamous cell carcinoma			

subjects affected / exposed	2 / 138 (1.45%)	7 / 692 (1.01%)	1 / 138 (0.72%)
occurrences (all)	2	8	1
Acrochordon			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Breast cancer			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Lipoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Lobular breast carcinoma in situ			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Melanocytic naevus			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Paget's disease of nipple			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Prostate cancer			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Seborrhoeic keratosis			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Skin papilloma			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	3	3	0
Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 138 (0.72%)	6 / 692 (0.87%)	2 / 138 (1.45%)
occurrences (all)	1	6	2
Uterine leiomyoma			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Sweat gland tumour			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Myelodysplastic syndrome			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Leiomyoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Large intestine benign neoplasm			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Large cell lung cancer			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Keratoacanthoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Bladder transitional cell carcinoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			
Angiopathy			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Aortic arteriosclerosis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Aortic aneurysm			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Arteriosclerosis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Surgical and medical procedures			
Hypotension			

subjects affected / exposed	2 / 138 (1.45%)	19 / 692 (2.75%)	3 / 138 (2.17%)
occurrences (all)	2	21	3
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	2 / 138 (1.45%)
occurrences (all)	0	2	2
Aortic stenosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Ischaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Poor venous access			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Tooth extraction			
subjects affected / exposed	2 / 138 (1.45%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	2	0	0
Astringent therapy			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	1 / 138 (0.72%)
occurrences (all)	1	0	1
Central venous catheter removal			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	1 / 138 (0.72%)
occurrences (all)	1	0	1
Cholecystectomy			
subjects affected / exposed	0 / 138 (0.00%)	0 / 692 (0.00%)	1 / 138 (0.72%)
occurrences (all)	0	0	1
Foot operation			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Hip arthroplasty			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Mass excision			
subjects affected / exposed	0 / 138 (0.00%)	0 / 692 (0.00%)	1 / 138 (0.72%)
occurrences (all)	0	0	1
Nephrostomy			

subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Shoulder arthroplasty			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Skin neoplasm excision			
subjects affected / exposed	0 / 138 (0.00%)	0 / 692 (0.00%)	1 / 138 (0.72%)
occurrences (all)	0	0	1
Venous thrombosis limb			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Venous thrombosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Varicose vein			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	1	4	1
Varicose ulceration			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Thrombosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Thrombophlebitis superficial			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Thrombophlebitis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Subclavian vein thrombosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Spider vein			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Phlebitis superficial			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Phlebitis			
subjects affected / exposed	2 / 138 (1.45%)	6 / 692 (0.87%)	3 / 138 (2.17%)
occurrences (all)	2	7	3
Peripheral venous disease			
subjects affected / exposed	3 / 138 (2.17%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	4	5	1
Peripheral ischaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Peripheral coldness			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Pallor			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Orthostatic hypotension			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Intermittent claudication			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Hypertensive crisis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Hypertension			
subjects affected / exposed	18 / 138 (13.04%)	45 / 692 (6.50%)	5 / 138 (3.62%)
occurrences (all)	27	57	6
Hyperaemia			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Hot flush			
subjects affected / exposed	1 / 138 (0.72%)	8 / 692 (1.16%)	1 / 138 (0.72%)
occurrences (all)	1	16	1
Haemorrhage			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Haematoma			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	2	5	1
Flushing			
subjects affected / exposed	2 / 138 (1.45%)	8 / 692 (1.16%)	2 / 138 (1.45%)
occurrences (all)	2	8	2
Essential hypertension			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Embolism			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Deep vein thrombosis			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	1	3	0
Cataract operation			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	4 / 138 (2.90%)
occurrences (all)	1	0	5
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	32 / 138 (23.19%)	159 / 692 (22.98%)	28 / 138 (20.29%)
occurrences (all)	45	258	49
Fatigue			
subjects affected / exposed	30 / 138 (21.74%)	115 / 692 (16.62%)	19 / 138 (13.77%)
occurrences (all)	46	157	25
Asthenia			
subjects affected / exposed	27 / 138 (19.57%)	113 / 692 (16.33%)	19 / 138 (13.77%)
occurrences (all)	43	167	28
Chest pain			
subjects affected / exposed	11 / 138 (7.97%)	27 / 692 (3.90%)	7 / 138 (5.07%)
occurrences (all)	12	29	7
Infusion site erythema			

subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences (all)	6	16	0
Chills			
subjects affected / exposed	8 / 138 (5.80%)	40 / 692 (5.78%)	9 / 138 (6.52%)
occurrences (all)	8	47	9
Influenza like illness			
subjects affected / exposed	6 / 138 (4.35%)	20 / 692 (2.89%)	6 / 138 (4.35%)
occurrences (all)	24	45	9
Mucosal inflammation			
subjects affected / exposed	6 / 138 (4.35%)	25 / 692 (3.61%)	7 / 138 (5.07%)
occurrences (all)	6	27	8
Oedema peripheral			
subjects affected / exposed	6 / 138 (4.35%)	38 / 692 (5.49%)	7 / 138 (5.07%)
occurrences (all)	6	40	8
Chest discomfort			
subjects affected / exposed	3 / 138 (2.17%)	10 / 692 (1.45%)	3 / 138 (2.17%)
occurrences (all)	3	10	3
General physical health deterioration			
subjects affected / exposed	3 / 138 (2.17%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences (all)	3	5	0
Hyperthermia			
subjects affected / exposed	3 / 138 (2.17%)	7 / 692 (1.01%)	1 / 138 (0.72%)
occurrences (all)	4	8	1
Injection site induration			
subjects affected / exposed	3 / 138 (2.17%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	9	17	2
Infusion site inflammation			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Injection site pain			
subjects affected / exposed	3 / 138 (2.17%)	24 / 692 (3.47%)	6 / 138 (4.35%)
occurrences (all)	3	34	7
Oedema			
subjects affected / exposed	3 / 138 (2.17%)	9 / 692 (1.30%)	2 / 138 (1.45%)
occurrences (all)	3	9	2
Pain			

subjects affected / exposed	3 / 138 (2.17%)	8 / 692 (1.16%)	2 / 138 (1.45%)
occurrences (all)	3	8	2
Hypothermia			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	2	7	0
Injection site discomfort			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Injection site mass			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	2 / 138 (1.45%)
occurrences (all)	0	3	3
Malaise			
subjects affected / exposed	2 / 138 (1.45%)	10 / 692 (1.45%)	1 / 138 (0.72%)
occurrences (all)	2	10	1
Peripheral swelling			
subjects affected / exposed	2 / 138 (1.45%)	7 / 692 (1.01%)	0 / 138 (0.00%)
occurrences (all)	2	8	0
Administration site extravasation			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	1	6	0
Administration site inflammation			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Application site erythema			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Application site pain			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Catheter site thrombosis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Cyst			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Discomfort			

subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Facial pain			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Feeling abnormal			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Feeling cold			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	1	3	0
Feeling hot			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	0	5	1
Feeling of body temperature change			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Granuloma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Inflammation			
subjects affected / exposed	0 / 138 (0.00%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	0	6	1
Injection site erythema			
subjects affected / exposed	10 / 138 (7.25%)	38 / 692 (5.49%)	9 / 138 (6.52%)
occurrences (all)	11	46	14
Infusion site haematoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Injection site inflammation			
subjects affected / exposed	0 / 138 (0.00%)	8 / 692 (1.16%)	3 / 138 (2.17%)
occurrences (all)	0	9	3
Injection site bruising			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	1	5	1
Infusion site pain			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Infusion site rash			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	3	1
Injection site discolouration			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	1	3	1
Injection site haematoma			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences (all)	2	5	0
Injection site hypersensitivity			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Injection site irritation			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Injection site pruritus			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Performance status decreased			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Injection site reaction			
subjects affected / exposed	1 / 138 (0.72%)	10 / 692 (1.45%)	1 / 138 (0.72%)
occurrences (all)	2	13	1
Injection site swelling			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	1	3	0
Injection site thrombosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Injection site warmth			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Localised oedema			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Polyp			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Puncture site erythema			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Puncture site pain			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	1	3	1
Unevaluable event			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Vessel puncture site haematoma			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Xerosis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Swelling			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Injection site rash			
subjects affected / exposed	0 / 138 (0.00%)	8 / 692 (1.16%)	1 / 138 (0.72%)
occurrences (all)	0	9	1
Infusion site extravasation			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	0	3	0
Axillary pain			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Administration site pain			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Catheter site haemorrhage			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Face oedema			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Implant site haematoma			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Haemorrhagic cyst			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Injection site oedema			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Injection site plaque			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Thirst			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			
Hypogammaglobulinaemia			
subjects affected / exposed	9 / 138 (6.52%)	26 / 692 (3.76%)	9 / 138 (6.52%)
occurrences (all)	9	26	9
Hypersensitivity			
subjects affected / exposed	3 / 138 (2.17%)	7 / 692 (1.01%)	0 / 138 (0.00%)
occurrences (all)	3	7	0
Immune system disorder			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Iodine allergy			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Seasonal allergy			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	2 / 138 (1.45%)
occurrences (all)	1	4	2

Sarcoidosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Immunodeficiency			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Drug hypersensitivity			
subjects affected / exposed	0 / 138 (0.00%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences (all)	0	7	0
Cytokine release syndrome			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	4 / 138 (2.90%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	4	0	0
Amenorrhoea			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Cystocele			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Dysmenorrhoea			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Erectile dysfunction			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Menstrual disorder			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Ovarian cyst			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	1 / 138 (0.72%)
occurrences (all)	1	0	1
Pelvic discomfort			

subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Pelvic pain			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	1 / 138 (0.72%)
occurrences (all)	2	0	1
Premature menopause			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	2	0	0
Pruritus genital			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Testicular oedema			
subjects affected / exposed	0 / 138 (0.00%)	0 / 692 (0.00%)	1 / 138 (0.72%)
occurrences (all)	0	0	1
Testicular pain			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Vaginal discharge			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	1 / 138 (0.72%)
occurrences (all)	1	0	1
Vulvovaginal erythema			
subjects affected / exposed	0 / 138 (0.00%)	0 / 692 (0.00%)	1 / 138 (0.72%)
occurrences (all)	0	0	1
Prostatic discomfort			
subjects affected / exposed	1 / 138 (0.72%)	0 / 692 (0.00%)	0 / 138 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	47 / 138 (34.06%)	135 / 692 (19.51%)	24 / 138 (17.39%)
occurrences (all)	72	185	37
Oropharyngeal pain			
subjects affected / exposed	15 / 138 (10.87%)	39 / 692 (5.64%)	5 / 138 (3.62%)
occurrences (all)	15	40	5
Dysphonia			

subjects affected / exposed	6 / 138 (4.35%)	14 / 692 (2.02%)	3 / 138 (2.17%)
occurrences (all)	7	18	4
Dyspnoea			
subjects affected / exposed	6 / 138 (4.35%)	55 / 692 (7.95%)	11 / 138 (7.97%)
occurrences (all)	7	62	11
Rhinorrhoea			
subjects affected / exposed	6 / 138 (4.35%)	14 / 692 (2.02%)	2 / 138 (1.45%)
occurrences (all)	6	14	2
Productive cough			
subjects affected / exposed	5 / 138 (3.62%)	25 / 692 (3.61%)	8 / 138 (5.80%)
occurrences (all)	5	28	8
Epistaxis			
subjects affected / exposed	3 / 138 (2.17%)	12 / 692 (1.73%)	3 / 138 (2.17%)
occurrences (all)	3	15	3
Rhinitis allergic			
subjects affected / exposed	3 / 138 (2.17%)	11 / 692 (1.59%)	2 / 138 (1.45%)
occurrences (all)	3	11	2
Asthma			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	2	6	3
Nasal congestion			
subjects affected / exposed	2 / 138 (1.45%)	8 / 692 (1.16%)	2 / 138 (1.45%)
occurrences (all)	2	8	2
Pharyngeal parasthesia			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	2	3	0
Pleural effusion			
subjects affected / exposed	2 / 138 (1.45%)	6 / 692 (0.87%)	2 / 138 (1.45%)
occurrences (all)	2	6	2
Sleep apnoea syndrome			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	2	3	0
Throat irritation			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	2	5	2
Atelectasis			

subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Bronchial disorder			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Bronchial obstruction			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Bronchiectasis			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Bronchitis chronic			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Bronchospasm			
subjects affected / exposed	1 / 138 (0.72%)	7 / 692 (1.01%)	2 / 138 (1.45%)
occurrences (all)	1	7	2
Catarrh			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	0	3	1
Dyspnoea exertional			
subjects affected / exposed	0 / 138 (0.00%)	6 / 692 (0.87%)	1 / 138 (0.72%)
occurrences (all)	0	7	1
Haemoptysis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Increased upper airway secretion			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Laryngeal pain			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Larynx irritation			

subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Lung disorder			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	2 / 138 (1.45%)
occurrences (all)	1	4	2
Nasal pruritus			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	2
Orthopnoea			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Painful respiration			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Pharyngeal inflammation			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Pleuritic pain			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	1	3	1
Pulmonary embolism			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	1	5	1
Pulmonary fibrosis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Upper respiratory tract inflammation			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	3	0
Upper-airway cough syndrome			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Wheezing			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	2 / 138 (1.45%)
occurrences (all)	0	4	2
Upper airway obstruction			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Tracheomalacia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Throat tightness			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Sneezing			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Sinus polyp			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Sinus disorder			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Sinus congestion			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Rhonchi			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Rhinitis atrophic			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Rales			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pulmonary mass			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pulmonary hypertension			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Pulmonary arterial hypertension			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pneumonia aspiration			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pleurisy			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Oropharyngeal discomfort			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Obstructive airways disorder			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Obliterative bronchiolitis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Noninfective bronchitis			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences (all)	0	4	0
Nasal polyps			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Nasal obstruction			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Laryngospasm			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Interstitial lung disease			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hiccups			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Emphysema			

subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	2	3	0
Dry throat			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	5 / 138 (3.62%)	9 / 692 (1.30%)	2 / 138 (1.45%)
occurrences (all)	5	10	2
Bronchomalacia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Asthmatic crisis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Adenoidal hypertrophy			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Acute pulmonary oedema			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Depression			
subjects affected / exposed	8 / 138 (5.80%)	20 / 692 (2.89%)	2 / 138 (1.45%)
occurrences (all)	8	20	2
Insomnia			
subjects affected / exposed	7 / 138 (5.07%)	31 / 692 (4.48%)	5 / 138 (3.62%)
occurrences (all)	8	33	5
Sleep disorder			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	2	5	1
Stress			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Adjustment disorder with depressed mood			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Anxiety			
subjects affected / exposed	1 / 138 (0.72%)	22 / 692 (3.18%)	9 / 138 (6.52%)
occurrences (all)	1	23	9
Anxiety disorder			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Confusional state			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	1	5	1
Restlessness			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Panic attack			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Mood altered			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Loss of libido			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Feeling of despair			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Depressed mood			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Delirium			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Agitation			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Investigations			

Blood lactate dehydrogenase increased			
subjects affected / exposed	4 / 138 (2.90%)	14 / 692 (2.02%)	1 / 138 (0.72%)
occurrences (all)	4	16	1
Alanine aminitransferase increased			
subjects affected / exposed	3 / 138 (2.17%)	11 / 692 (1.59%)	3 / 138 (2.17%)
occurrences (all)	3	20	7
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 138 (2.17%)	11 / 692 (1.59%)	3 / 138 (2.17%)
occurrences (all)	3	13	4
CD4 lymphocytes decreased			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	3 / 138 (2.17%)
occurrences (all)	0	3	3
Blood bilirubin increased			
subjects affected / exposed	2 / 138 (1.45%)	6 / 692 (0.87%)	2 / 138 (1.45%)
occurrences (all)	2	6	2
Blood pressure abnormal			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Biopsy prostate			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 138 (0.72%)	8 / 692 (1.16%)	1 / 138 (0.72%)
occurrences (all)	1	9	1
Blood creatine increased			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Blood pressure increased			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	3	4	1
Cardiac murmur			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Electrocardiogram QT prolonged			

subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Transaminases increased			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	2	6	1
White blood cell count increased			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
White blood cell count decreased			
subjects affected / exposed	11 / 138 (7.97%)	46 / 692 (6.65%)	13 / 138 (9.42%)
occurrences (all)	19	72	21
Weight increased			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	0	6	1
Weight decreased			
subjects affected / exposed	6 / 138 (4.35%)	25 / 692 (3.61%)	4 / 138 (2.90%)
occurrences (all)	7	27	4
Transferrin saturation decreased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pulse abnormal			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Prostatic specific antigen increased			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Polymerase chain reaction positive			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Platelet count increased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Platelet count decreased			
subjects affected / exposed	14 / 138 (10.14%)	59 / 692 (8.53%)	10 / 138 (7.25%)
occurrences (all)	20	96	13
Oxygen saturation decrease			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Neutrophil count increased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Neutrophil count decreased			
subjects affected / exposed	28 / 138 (20.29%)	113 / 692 (16.33%)	29 / 138 (21.01%)
occurrences (all)	65	289	60
Lymphocyte count increased			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Lymphocyte count decreased			
subjects affected / exposed	13 / 138 (9.42%)	45 / 692 (6.50%)	14 / 138 (10.14%)
occurrences (all)	17	80	23
Liver palpable			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Liver function test increased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
International normalised ratio increased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
International normalised ratio decreased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Immunoglobulins decreased			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Hypophonesis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Histamine level increased			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Haemoglobin decreased			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	1	3	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 138 (0.72%)	6 / 692 (0.87%)	0 / 138 (0.00%)
occurrences (all)	1	8	0
Eosinophil count increased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Ejection fraction decreased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Coagulation time prolonged			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
C-reactive protein increased			
subjects affected / exposed	3 / 138 (2.17%)	17 / 692 (2.46%)	2 / 138 (1.45%)
occurrences (all)	3	17	2
Body temperature increased			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Blood urea increased			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Blood sodium decreased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Blood potassium decreased			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	1	3	1

Blood phosphorus decreased			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Blood magnesium decreased			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Blood iron decreased			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Blood immunoglobulin M decreased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Blood immunoglobulin G decreased			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences (all)	1	5	0
Blood glucose increased			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Blood folate decreased			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Blood creatinine increased			
subjects affected / exposed	4 / 138 (2.90%)	12 / 692 (1.73%)	4 / 138 (2.90%)
occurrences (all)	4	17	5
Blood cholesterol increased			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	2	3	1
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	4 / 138 (2.90%)	6 / 692 (0.87%)	0 / 138 (0.00%)
occurrences (all)	4	6	0
Infusion related reaction			
subjects affected / exposed	4 / 138 (2.90%)	23 / 692 (3.32%)	3 / 138 (2.17%)
occurrences (all)	4	24	3
Head injury			

subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	2 / 138 (1.45%)
occurrences (all)	0	2	2
Lumbar vertebral fracture			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Muscle strain			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	2	3	0
Procedural pain			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	2	3	0
Skin abrasion			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	3	3	0
Administration related reaction			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Animal bite			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Arthropod bite			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Dental restoration failure			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Fall			
subjects affected / exposed	1 / 138 (0.72%)	11 / 692 (1.59%)	4 / 138 (2.90%)
occurrences (all)	1	12	4
Foot fracture			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	1	3	1
Humerus fracture			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	1	3	0
Fracture			

subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	1	3	0
Joint dislocation			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Joint injury			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	2 / 138 (1.45%)
occurrences (all)	1	3	2
Ligament rupture			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Ligament sprain			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	0	3	1
Limb injury			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences (all)	1	5	0
Muscle rupture			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Pelvic fracture			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Post procedural haematoma			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Radiation injury			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Radiation skin injury			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Radius fracture			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Rib fracture			

subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Spinal compression fracture			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Thermal burn			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Tooth avulsion			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Tooth fracture			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	4	0
Toxicity to various agents			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Traumatic haematoma			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Upper limb fracture			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Wrist fracture			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Scratch			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Spinal fracture			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Procedural site reaction			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Post-traumatic pain			

subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Medication error			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hand fracture			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Laceration			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Epicondylitis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Craniocerebral injury			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 138 (0.00%)	10 / 692 (1.45%)	4 / 138 (2.90%)
occurrences (all)	0	10	4
Palpitations			
subjects affected / exposed	3 / 138 (2.17%)	9 / 692 (1.30%)	4 / 138 (2.90%)
occurrences (all)	3	11	5
Sinus tachycardia			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	3	4	0
Acute coronary syndrome			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Angina pectoris			
subjects affected / exposed	1 / 138 (0.72%)	7 / 692 (1.01%)	4 / 138 (2.90%)
occurrences (all)	1	8	5
Aortic valve incompetence			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0

Arrhythmia supraventricular			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Atrial flutter			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	0	4	1
Bradycardia			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Bundle branch block left			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Cardiac failure			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	1	3	0
Cardiac failure congestive			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Extrasystoles			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Hyperkinetic heart syndrome			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Left ventricular failure			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Mitral valve incompetence			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Myocardial ischaemia			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Supraventricular tachycardia			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0

Vantricular arrhythmia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Sinus bradycardia			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Pericardial effusion			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Left ventricular dysfunction			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Cardiac failure chronic			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Atrioventricular block complete			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Atrial tachycardia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Arrhythmia			
subjects affected / exposed	3 / 138 (2.17%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences (all)	3	5	0
Atrial fibrillation			
subjects affected / exposed	2 / 138 (1.45%)	8 / 692 (1.16%)	2 / 138 (1.45%)
occurrences (all)	3	12	2
Nervous system disorders			
Headache			
subjects affected / exposed	16 / 138 (11.59%)	68 / 692 (9.83%)	18 / 138 (13.04%)
occurrences (all)	24	92	25
Neuropathy peripheral			
subjects affected / exposed	8 / 138 (5.80%)	23 / 692 (3.32%)	7 / 138 (5.07%)
occurrences (all)	9	25	8
Dysgeusia			

subjects affected / exposed	7 / 138 (5.07%)	17 / 692 (2.46%)	3 / 138 (2.17%)
occurrences (all)	11	21	3
Peripheral sensory neuropathy			
subjects affected / exposed	4 / 138 (2.90%)	10 / 692 (1.45%)	3 / 138 (2.17%)
occurrences (all)	4	10	3
Presyncope			
subjects affected / exposed	4 / 138 (2.90%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	4	5	1
Amnesia			
subjects affected / exposed	3 / 138 (2.17%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	3	5	1
Sciatica			
subjects affected / exposed	3 / 138 (2.17%)	12 / 692 (1.73%)	4 / 138 (2.90%)
occurrences (all)	3	14	5
Syncope			
subjects affected / exposed	3 / 138 (2.17%)	10 / 692 (1.45%)	2 / 138 (1.45%)
occurrences (all)	3	10	2
Carotid arteriosclerosis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	2 / 138 (1.45%)
occurrences (all)	0	2	2
Memory impairment			
subjects affected / exposed	2 / 138 (1.45%)	6 / 692 (0.87%)	2 / 138 (1.45%)
occurrences (all)	2	6	2
Ageusia			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	1	3	0
Aphasia			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Aphonia			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Ataxia			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Cerebral ischaemia			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Cluster headache			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Diabetic neuropathy			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Facial paralysis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Neuralgia			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	1	4	1
Neuromuscular pain			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Nystagmus			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Parkinsonism			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Parosmia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Polyneuropathy			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	1	3	0
Sensorimotor disorder			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Vertebrobasilar insufficiency			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Tremor			

subjects affected / exposed	3 / 138 (2.17%)	13 / 692 (1.88%)	3 / 138 (2.17%)
occurrences (all)	3	15	4
Tension headache			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Somnolence			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	3 / 138 (2.17%)
occurrences (all)	0	4	3
Sensory disturbance			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Seizure			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Post herpetic neuralgia			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	1	5	2
Peripheral sensorimotor neuropathy			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Paraesthesia			
subjects affected / exposed	5 / 138 (3.62%)	29 / 692 (4.19%)	9 / 138 (6.52%)
occurrences (all)	5	29	9
Nerve root compression			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Nerve compression			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Lumbar radiculopathy			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Lethargy			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences (all)	2	5	0
Intention tremor			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hypotonia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hypokinesia			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Hypoaesthesia			
subjects affected / exposed	1 / 138 (0.72%)	6 / 692 (0.87%)	2 / 138 (1.45%)
occurrences (all)	1	8	3
Hypersomnia			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Hemiparesis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Formication			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Facial neuralgia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Dysgraphia			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Dysaesthesia			
subjects affected / exposed	1 / 138 (0.72%)	6 / 692 (0.87%)	3 / 138 (2.17%)
occurrences (all)	1	6	3
Dizziness			
subjects affected / exposed	16 / 138 (11.59%)	36 / 692 (5.20%)	8 / 138 (5.80%)
occurrences (all)	21	42	8
Disturbance in attention			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Cerebral microangiopathy			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Carpal tunnel syndrome			
subjects affected / exposed	3 / 138 (2.17%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	3	3	0
Burning sensation			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Balance disorder			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	2 / 138 (1.45%)
occurrences (all)	1	3	2
Arachnoid cyst			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Anosmia			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	48 / 138 (34.78%)	226 / 692 (32.66%)	51 / 138 (36.96%)
occurrences (all)	134	604	173
Anaemia			
subjects affected / exposed	23 / 138 (16.67%)	106 / 692 (15.32%)	21 / 138 (15.22%)
occurrences (all)	35	172	32
Leukopenia			
subjects affected / exposed	14 / 138 (10.14%)	52 / 692 (7.51%)	9 / 138 (6.52%)
occurrences (all)	47	126	18
Lymphopenia			
subjects affected / exposed	4 / 138 (2.90%)	16 / 692 (2.31%)	1 / 138 (0.72%)
occurrences (all)	13	34	1
Febrile neutropenia			
subjects affected / exposed	3 / 138 (2.17%)	15 / 692 (2.17%)	2 / 138 (1.45%)
occurrences (all)	3	22	8
Lymphadenopathy			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	3 / 138 (2.17%)
occurrences (all)	0	3	3

Agranulocytosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	3 / 138 (2.17%)
occurrences (all)	0	1	3
Haematotoxicity			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Pancytopenia			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	0	4	1
Thrombocytopenia			
subjects affected / exposed	9 / 138 (6.52%)	49 / 692 (7.08%)	10 / 138 (7.25%)
occurrences (all)	12	75	13
Microcytosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Lymphocytosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Leukocytosis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Lymph node pain			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Iron deficiency anaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hypoglobulinaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hypochromic anaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Eosinophilia			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences (all)	0	4	0

Coagulopathy			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	7 / 138 (5.07%)	18 / 692 (2.60%)	2 / 138 (1.45%)
occurrences (all)	10	21	2
Tinnitus			
subjects affected / exposed	5 / 138 (3.62%)	9 / 692 (1.30%)	2 / 138 (1.45%)
occurrences (all)	6	10	2
Ear pain			
subjects affected / exposed	4 / 138 (2.90%)	11 / 692 (1.59%)	2 / 138 (1.45%)
occurrences (all)	4	12	2
Deafness unilateral			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	2 / 138 (1.45%)
occurrences (all)	0	3	2
Deafness			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Hypoacusis			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	1	4	1
Tympanic membrane disorder			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Vestibular disorder			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Middle ear inflammation			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Eye disorders			
Eye pain			
subjects affected / exposed	4 / 138 (2.90%)	6 / 692 (0.87%)	0 / 138 (0.00%)
occurrences (all)	4	6	0
Dry eye			

subjects affected / exposed	3 / 138 (2.17%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences (all)	3	5	0
Cataract			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	3	5	2
Vision blurred			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	2	5	1
Visual impairment			
subjects affected / exposed	2 / 138 (1.45%)	6 / 692 (0.87%)	1 / 138 (0.72%)
occurrences (all)	2	6	1
Chalazion			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Diabetic retinopathy			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Eye inflammation			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Eye irritation			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Eye pruritus			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	2 / 138 (1.45%)
occurrences (all)	1	3	2
Eyelid oedema			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Glaucoma			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Noninfective conjunctivitis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Ocular hyperaemia			

subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	0	3	1
Periorbital oedema			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Visual acuity reduced			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Vitreous floaters			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Eyelid swelling			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Lacrimation increased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Eye discharge			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Entropion			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis allergic			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Conjunctival hyperaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	45 / 138 (32.61%)	199 / 692 (28.76%)	37 / 138 (26.81%)
occurrences (all)	63	312	65
Diarrhoea			
subjects affected / exposed	35 / 138 (25.36%)	143 / 692 (20.66%)	28 / 138 (20.29%)
occurrences (all)	50	211	36

Vomiting			
subjects affected / exposed	23 / 138 (16.67%)	96 / 692 (13.87%)	15 / 138 (10.87%)
occurrences (all)	32	160	22
Constipation			
subjects affected / exposed	21 / 138 (15.22%)	98 / 692 (14.16%)	15 / 138 (10.87%)
occurrences (all)	26	129	22
Abdominal pain			
subjects affected / exposed	13 / 138 (9.42%)	57 / 692 (8.24%)	13 / 138 (9.42%)
occurrences (all)	15	74	23
Abdominal pain upper			
subjects affected / exposed	11 / 138 (7.97%)	39 / 692 (5.64%)	4 / 138 (2.90%)
occurrences (all)	16	49	5
Gastrooesophageal reflux disease			
subjects affected / exposed	11 / 138 (7.97%)	20 / 692 (2.89%)	7 / 138 (5.07%)
occurrences (all)	13	24	9
Dyspepsia			
subjects affected / exposed	10 / 138 (7.25%)	26 / 692 (3.76%)	7 / 138 (5.07%)
occurrences (all)	10	27	7
Stomatitis			
subjects affected / exposed	5 / 138 (3.62%)	17 / 692 (2.46%)	3 / 138 (2.17%)
occurrences (all)	5	18	4
Toothache			
subjects affected / exposed	5 / 138 (3.62%)	9 / 692 (1.30%)	2 / 138 (1.45%)
occurrences (all)	5	9	2
Aphthous ulcer			
subjects affected / exposed	0 / 138 (0.00%)	6 / 692 (0.87%)	3 / 138 (2.17%)
occurrences (all)	0	6	3
Colitis			
subjects affected / exposed	3 / 138 (2.17%)	6 / 692 (0.87%)	0 / 138 (0.00%)
occurrences (all)	5	8	0
Haemorrhoids			
subjects affected / exposed	0 / 138 (0.00%)	12 / 692 (1.73%)	3 / 138 (2.17%)
occurrences (all)	0	12	3
Mouth ulceration			
subjects affected / exposed	3 / 138 (2.17%)	12 / 692 (1.73%)	3 / 138 (2.17%)
occurrences (all)	4	15	4

Oral pain			
subjects affected / exposed	3 / 138 (2.17%)	15 / 692 (2.17%)	5 / 138 (3.62%)
occurrences (all)	3	16	5
Abdominal discomfort			
subjects affected / exposed	0 / 138 (0.00%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	0	5	2
Abdominal distension			
subjects affected / exposed	2 / 138 (1.45%)	7 / 692 (1.01%)	1 / 138 (0.72%)
occurrences (all)	2	8	1
Enterocolitis			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Gastrointestinal disorder			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	2	5	2
Hiatus hernia			
subjects affected / exposed	2 / 138 (1.45%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	2	4	1
Inguinal hernia			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	2	3	0
Irritable bowel syndrome			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Oesophagitis			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Tongue ulceration			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	2 / 138 (1.45%)
occurrences (all)	0	4	2
Tooth disorder			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	2 / 138 (1.45%)
occurrences (all)	0	2	2
Umbilical hernia			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0

Abdominal pain lower			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	3	2
Abdominal tenderness			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	0	3	1
Crohn's disease			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	2	2
Diverticulum intestinal			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Dry mouth			
subjects affected / exposed	1 / 138 (0.72%)	10 / 692 (1.45%)	1 / 138 (0.72%)
occurrences (all)	1	10	1
Dysphagia			
subjects affected / exposed	1 / 138 (0.72%)	10 / 692 (1.45%)	1 / 138 (0.72%)
occurrences (all)	1	10	1
Eructation			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Faecaloma			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Faeces soft			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Flatulence			
subjects affected / exposed	1 / 138 (0.72%)	7 / 692 (1.01%)	1 / 138 (0.72%)
occurrences (all)	1	7	1
Gastritis			
subjects affected / exposed	1 / 138 (0.72%)	12 / 692 (1.73%)	6 / 138 (4.35%)
occurrences (all)	1	12	6
Gastrointestinal hypomotility			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1

Gastrointestinal sounds abnormal			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Gingival bleeding			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Haematochezia			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	2 / 138 (1.45%)
occurrences (all)	1	3	2
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	0	4	1
Haemorrhoids thrombosed			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Ileal ulcer			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Melaena			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Noninfective gingivitis			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Odynophagia			
subjects affected / exposed	1 / 138 (0.72%)	7 / 692 (1.01%)	2 / 138 (1.45%)
occurrences (all)	1	10	5
Pancreatic cyst			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Proctalgia			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0

Rectal polyp			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Sensitivity of teeth			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Tongue coated			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Tongue geographic			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Tooth loss			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Ascites			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	0	4	0
Anal fissure			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	3	0
Paraesthesia oral			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	0	3	0
Gastric ulcer			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Lip ulceration			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Rectal haemorrhage			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Anal haemorrhage			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0

Change in bowel habit			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Chronic gastritis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Tooth development disorder			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Salivary hypersecretion			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Perianal erythema			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pancreatic duct dilatation			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Oral disorder			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Large intestinal ulcer			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Intestinal obstruction			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Impaired gastric emptying			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal toxicity			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal inflammation			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0

Food poisoning			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Epigastric discomfort			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Dyschezia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Defaecation urgency			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	19 / 138 (13.77%)	76 / 692 (10.98%)	18 / 138 (13.04%)
occurrences (all)	24	97	23
Pruritus			
subjects affected / exposed	11 / 138 (7.97%)	51 / 692 (7.37%)	9 / 138 (6.52%)
occurrences (all)	14	61	12
Alopecia			
subjects affected / exposed	6 / 138 (4.35%)	23 / 692 (3.32%)	6 / 138 (4.35%)
occurrences (all)	6	26	7
Erythema			
subjects affected / exposed	6 / 138 (4.35%)	29 / 692 (4.19%)	6 / 138 (4.35%)
occurrences (all)	7	39	7
Eczema			
subjects affected / exposed	3 / 138 (2.17%)	12 / 692 (1.73%)	4 / 138 (2.90%)
occurrences (all)	3	14	4
Hyperhidrosis			
subjects affected / exposed	3 / 138 (2.17%)	15 / 692 (2.17%)	2 / 138 (1.45%)
occurrences (all)	3	15	2
Night sweats			
subjects affected / exposed	3 / 138 (2.17%)	19 / 692 (2.75%)	3 / 138 (2.17%)
occurrences (all)	5	22	4
Skin lesion			

subjects affected / exposed	3 / 138 (2.17%)	19 / 692 (2.75%)	7 / 138 (5.07%)
occurrences (all)	3	22	8
Urticaria			
subjects affected / exposed	3 / 138 (2.17%)	15 / 692 (2.17%)	2 / 138 (1.45%)
occurrences (all)	3	20	7
Actinic keratosis			
subjects affected / exposed	2 / 138 (1.45%)	10 / 692 (1.45%)	3 / 138 (2.17%)
occurrences (all)	2	11	3
Hyperkeratosis			
subjects affected / exposed	2 / 138 (1.45%)	8 / 692 (1.16%)	2 / 138 (1.45%)
occurrences (all)	2	8	2
Psoriasis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	2 / 138 (1.45%)
occurrences (all)	0	2	2
Purpura			
subjects affected / exposed	2 / 138 (1.45%)	4 / 692 (0.58%)	2 / 138 (1.45%)
occurrences (all)	2	4	2
Rash erythematous			
subjects affected / exposed	2 / 138 (1.45%)	7 / 692 (1.01%)	1 / 138 (0.72%)
occurrences (all)	2	7	1
Angioedema			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Dermatitis bullous			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	4	4	0
Granulomatous rosacea			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Neurodermatitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Panniculitis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Pityriasis rosea			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Rash follicular			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Rash macular			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Rosacea			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Seborrhoeic dermatitis			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	1	5	3
Skin exfoliation			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Skin reaction			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	1	6	2
Swelling face			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Stasis dermatitis			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	1	3	1
Skin ulcer			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	3 / 138 (2.17%)
occurrences (all)	1	4	3
Skin swelling			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Skin mass			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Skin disorder			

subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Sebaceous hyperplasia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Rash pruritic			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	0	3	0
Rash papular			
subjects affected / exposed	0 / 138 (0.00%)	6 / 692 (0.87%)	1 / 138 (0.72%)
occurrences (all)	0	8	1
Rash maculo-papular			
subjects affected / exposed	0 / 138 (0.00%)	8 / 692 (1.16%)	2 / 138 (1.45%)
occurrences (all)	0	10	3
Rash generalised			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pruritus generalised			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	1	4	1
Pruritus allergic			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Prurigo			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Perioral dermatitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pain of skin			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Nail discolouration			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Macule			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Intertrigo			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	2 / 138 (1.45%)
occurrences (all)	0	2	2
Hypertrichiosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Exfoliative rash			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Erythema nodosum			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Erythema multiforme			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Eczema nummular			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Ecchymosis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Dry skin			
subjects affected / exposed	4 / 138 (2.90%)	10 / 692 (1.45%)	3 / 138 (2.17%)
occurrences (all)	5	11	3
Drug eruption			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences (all)	1	5	0
Dermatomyositis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Dermatitis atopic			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Dermatitis allergic			

subjects affected / exposed	2 / 138 (1.45%)	6 / 692 (0.87%)	2 / 138 (1.45%)
occurrences (all)	2	6	2
Dermatitis			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	2	5	2
Dermal cyst			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Decubitus ulcer			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Blood blister			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Acne			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Pollakiuria			
subjects affected / exposed	3 / 138 (2.17%)	9 / 692 (1.30%)	1 / 138 (0.72%)
occurrences (all)	3	10	1
Dysuria			
subjects affected / exposed	2 / 138 (1.45%)	13 / 692 (1.88%)	6 / 138 (4.35%)
occurrences (all)	2	14	6
Haematuria			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	2	5	1
Renal failure			
subjects affected / exposed	0 / 138 (0.00%)	8 / 692 (1.16%)	2 / 138 (1.45%)
occurrences (all)	0	9	2
Strangury			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	2 / 138 (1.45%)
occurrences (all)	0	3	2
Azotaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1

Bladder disorder			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Bladder hypertrophy			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Chronic kidney disease			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Hypertonic bladder			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Nephroangiosclerosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Nephrolithiasis			
subjects affected / exposed	1 / 138 (0.72%)	6 / 692 (0.87%)	3 / 138 (2.17%)
occurrences (all)	1	6	3
Nocturia			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Renal colic			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Urethral haemorrhage			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Urinary incontinence			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	1	7	3
Urinary tract obstruction			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Urinary tract pain			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0

Urinary retention			
subjects affected / exposed	3 / 138 (2.17%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	3	5	1
Renal pain			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Renal impairment			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Renal cyst			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	2 / 138 (1.45%)
occurrences (all)	1	3	2
Renal atrophy			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Polyuria			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Micturition urgency			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Leukocyturia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Cystitis haemorrhagic			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Acute kidney injury			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	0	3	1
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	5 / 138 (3.62%)	16 / 692 (2.31%)	5 / 138 (3.62%)
occurrences (all)	5	17	5
Osteoporosis			

subjects affected / exposed	4 / 138 (2.90%)	7 / 692 (1.01%)	1 / 138 (0.72%)
occurrences (all)	4	8	1
Spinal osteoarthritis			
subjects affected / exposed	2 / 138 (1.45%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	2	4	1
Chondrocalcinosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Exostosis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Limb mass			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Muscle tightness			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Muscular weakness			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	1	3	0
Musculoskeletal discomfort			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Osteopenia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Periostitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Sjogren's syndrome			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Spinal column stenosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Spinal pain			

subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences (all)	1	4	0
Tenosynovitis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Tendonitis			
subjects affected / exposed	3 / 138 (2.17%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	3	4	1
Tendon disorder			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Synovial cyst			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Spondylitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Rotator cuff syndrome			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Periarthritis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Polyarthritis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pain in jaw			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	2 / 138 (1.45%)
occurrences (all)	0	2	2
Pain in extremity			
subjects affected / exposed	10 / 138 (7.25%)	43 / 692 (6.21%)	10 / 138 (7.25%)
occurrences (all)	10	46	11
Osteochondrosis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Osteoarthritis			

subjects affected / exposed	3 / 138 (2.17%)	14 / 692 (2.02%)	5 / 138 (3.62%)
occurrences (all)	3	15	5
Osteitis deformans			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Neck pain			
subjects affected / exposed	4 / 138 (2.90%)	11 / 692 (1.59%)	3 / 138 (2.17%)
occurrences (all)	5	12	3
Myofascial pain syndrome			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Musculoskeletal stiffness			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Musculoskeletal pain			
subjects affected / exposed	5 / 138 (3.62%)	22 / 692 (3.18%)	6 / 138 (4.35%)
occurrences (all)	5	22	6
Musculoskeletal chest pain			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	2	5	2
Muscle spasms			
subjects affected / exposed	10 / 138 (7.25%)	25 / 692 (3.61%)	5 / 138 (3.62%)
occurrences (all)	10	28	7
Muscle fatigue			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Muscle contracture			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Mobility decreased			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Joint swelling			
subjects affected / exposed	2 / 138 (1.45%)	7 / 692 (1.01%)	3 / 138 (2.17%)
occurrences (all)	3	8	3
Limb discomfort			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Joint stiffness			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Intervertebral disc protrusion			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Groin pain			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	1	4	2
Foot deformity			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Flank pain			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	1	6	1
Bursitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Bone pain			
subjects affected / exposed	2 / 138 (1.45%)	17 / 692 (2.46%)	3 / 138 (2.17%)
occurrences (all)	2	17	3
Back pain			
subjects affected / exposed	14 / 138 (10.14%)	62 / 692 (8.96%)	13 / 138 (9.42%)
occurrences (all)	16	72	19
Axillary mass			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Arthritis			
subjects affected / exposed	0 / 138 (0.00%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	0	5	2
Arthralgia			
subjects affected / exposed	15 / 138 (10.87%)	52 / 692 (7.51%)	14 / 138 (10.14%)
occurrences (all)	22	68	23
Infections and infestations			

Nasopharyngitis			
subjects affected / exposed	29 / 138 (21.01%)	72 / 692 (10.40%)	24 / 138 (17.39%)
occurrences (all)	55	120	36
Bronchitis			
subjects affected / exposed	24 / 138 (17.39%)	78 / 692 (11.27%)	21 / 138 (15.22%)
occurrences (all)	55	126	27
Upper respiratory tract infection			
subjects affected / exposed	24 / 138 (17.39%)	63 / 692 (9.10%)	20 / 138 (14.49%)
occurrences (all)	36	85	26
Influenza			
subjects affected / exposed	20 / 138 (14.49%)	56 / 692 (8.09%)	14 / 138 (10.14%)
occurrences (all)	23	65	18
Rhinitis			
subjects affected / exposed	19 / 138 (13.77%)	42 / 692 (6.07%)	9 / 138 (6.52%)
occurrences (all)	21	46	9
Lower respiratory tract infection			
subjects affected / exposed	17 / 138 (12.32%)	46 / 692 (6.65%)	9 / 138 (6.52%)
occurrences (all)	37	76	14
Pneumonia			
subjects affected / exposed	17 / 138 (12.32%)	44 / 692 (6.36%)	10 / 138 (7.25%)
occurrences (all)	22	55	13
Herpes zoster			
subjects affected / exposed	16 / 138 (11.59%)	46 / 692 (6.65%)	12 / 138 (8.70%)
occurrences (all)	18	50	12
Sinusitis			
subjects affected / exposed	14 / 138 (10.14%)	45 / 692 (6.50%)	16 / 138 (11.59%)
occurrences (all)	27	67	21
Conjunctivitis			
subjects affected / exposed	12 / 138 (8.70%)	24 / 692 (3.47%)	4 / 138 (2.90%)
occurrences (all)	14	27	5
Urinary tract infection			
subjects affected / exposed	11 / 138 (7.97%)	55 / 692 (7.95%)	14 / 138 (10.14%)
occurrences (all)	14	73	22
Lung infection			
subjects affected / exposed	10 / 138 (7.25%)	24 / 692 (3.47%)	5 / 138 (3.62%)
occurrences (all)	15	32	5

Oral herpes			
subjects affected / exposed	9 / 138 (6.52%)	25 / 692 (3.61%)	4 / 138 (2.90%)
occurrences (all)	17	35	5
Viral infection			
subjects affected / exposed	7 / 138 (5.07%)	11 / 692 (1.59%)	2 / 138 (1.45%)
occurrences (all)	8	12	2
Acute sinusitis			
subjects affected / exposed	5 / 138 (3.62%)	7 / 692 (1.01%)	1 / 138 (0.72%)
occurrences (all)	6	7	1
Cystitis			
subjects affected / exposed	4 / 138 (2.90%)	6 / 692 (0.87%)	0 / 138 (0.00%)
occurrences (all)	4	6	0
Respiratory tract infection			
subjects affected / exposed	4 / 138 (2.90%)	24 / 692 (3.47%)	10 / 138 (7.25%)
occurrences (all)	5	36	19
Tracheobronchitis			
subjects affected / exposed	4 / 138 (2.90%)	6 / 692 (0.87%)	1 / 138 (0.72%)
occurrences (all)	4	6	1
Candida infection			
subjects affected / exposed	3 / 138 (2.17%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences (all)	3	5	0
Ear infection			
subjects affected / exposed	3 / 138 (2.17%)	14 / 692 (2.02%)	4 / 138 (2.90%)
occurrences (all)	4	17	4
Oral candidiasis			
subjects affected / exposed	3 / 138 (2.17%)	14 / 692 (2.02%)	3 / 138 (2.17%)
occurrences (all)	3	15	4
Pharyngitis			
subjects affected / exposed	3 / 138 (2.17%)	9 / 692 (1.30%)	3 / 138 (2.17%)
occurrences (all)	4	13	6
Pulpitis dental			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	3 / 138 (2.17%)
occurrences (all)	0	6	3
Tonsillitis			
subjects affected / exposed	3 / 138 (2.17%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	3	6	3

Tracheitis			
subjects affected / exposed	3 / 138 (2.17%)	8 / 692 (1.16%)	3 / 138 (2.17%)
occurrences (all)	3	8	3
Viral upper respiratory tract infection			
subjects affected / exposed	3 / 138 (2.17%)	7 / 692 (1.01%)	0 / 138 (0.00%)
occurrences (all)	3	7	0
Gastroenteritis			
subjects affected / exposed	2 / 138 (1.45%)	11 / 692 (1.59%)	7 / 138 (5.07%)
occurrences (all)	2	12	7
Gastrointestinal infection			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	2	3	1
Gingivitis			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	3	6	2
Herpes simplex			
subjects affected / exposed	2 / 138 (1.45%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	2	4	1
Hordeolum			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	3	3	0
Laryngitis			
subjects affected / exposed	2 / 138 (1.45%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences (all)	2	4	0
Onychomycosis			
subjects affected / exposed	2 / 138 (1.45%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	2	5	2
Oral fungal infection			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	2	6	2
Oral infection			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Respiratory tract infection viral			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	2	4	0

Subcutaneous abscess			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	2	9	6
Tooth abscess			
subjects affected / exposed	2 / 138 (1.45%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	2	5	1
Vaginal infection			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	3	4	1
Viral pharyngitis			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	2	3	0
Anal abscess			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Angular cheilitis			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Arthritis bacterial			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Bacterial infection			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Blastocystis infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Bartholinitis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Body tinea			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Campylobacter colitis			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1

Campylobacter gastroenteritis			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Campylobacter infection			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Cellulitis			
subjects affected / exposed	1 / 138 (0.72%)	8 / 692 (1.16%)	2 / 138 (1.45%)
occurrences (all)	1	9	2
Chlamydial infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Cytomegalovirus infection			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Dacryocanaliculitis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Device related infection			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Device related sepsis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Diarrhoea infectious			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Diverticulitis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Epstein-Barr virus infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Erysipelas			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	2 / 138 (1.45%)
occurrences (all)	1	4	2

Escherichia urinary tract infection			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	2	8	4
Eye infection			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	0	3	1
Eyelid infection			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Folliculitis			
subjects affected / exposed	1 / 138 (0.72%)	8 / 692 (1.16%)	2 / 138 (1.45%)
occurrences (all)	1	12	5
Fungal infection			
subjects affected / exposed	1 / 138 (0.72%)	6 / 692 (0.87%)	1 / 138 (0.72%)
occurrences (all)	1	6	1
Fungal skin infection			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	2 / 138 (1.45%)
occurrences (all)	2	5	3
Furuncle			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	1	7	4
Gastroenteritis viral			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Genital herpes simplex			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Haemophilus infection			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Helicobacter gastritis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Hepatitis B			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0

Hepatitis viral			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Herpes virus infection			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	1	4	2
Infected bite			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Infection			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	1	4	1
Infectious colitis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Injection site cellulitis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Labyrinthitis			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	3	0
Lip infection			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Lower respiratory tract infection viral			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Lymphangitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Mucosal infection			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Nail infection			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1

Otitis externa			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	2
Otitis media			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Parainfluenzae virus infection			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Periorbital infection			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Pertussis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Pharyngotonsillitis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	0	2	1
Pneumonia bacterial			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Pneumonia fungal			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Postoperative wound infection			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Proteus infection			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	3	3	0
Rash pustular			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	1 / 138 (0.72%)
occurrences (all)	1	5	1
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0

Skin infection			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	3 / 138 (2.17%)
occurrences (all)	1	4	3
Staphylococcal infection			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	1	3	0
Tinea pedis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Tooth infection			
subjects affected / exposed	1 / 138 (0.72%)	5 / 692 (0.72%)	2 / 138 (1.45%)
occurrences (all)	2	6	2
Trichomoniasis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Varicella zoster virus infection			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	1	2	0
Viral parotitis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Vulvitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Vulvovaginal mycotic infection			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	3	5	2
Wound infection			
subjects affected / exposed	1 / 138 (0.72%)	3 / 692 (0.43%)	2 / 138 (1.45%)
occurrences (all)	1	3	2
Bacteuria			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Ureaplasma infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0

Sinusitis bacterial			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Superinfection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Sepsis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Rectal abscess			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pyoderma			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Pyelonephritis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Puncture site abscess			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pseudomonas infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Pseudomembranous colitis			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Paronychia			
subjects affected / exposed	0 / 138 (0.00%)	3 / 692 (0.43%)	0 / 138 (0.00%)
occurrences (all)	0	6	0
Orchitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Oesophageal candidiasis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0

Nasal herpes			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Meningitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Herpes zoster oticus			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Herpes zoster infection neurological			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hepatic infection fungal			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal fungal infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis salmonella			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Endocarditis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Cystitis Escherichia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Balanitis candida			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Arthritis infective			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Application site cellulitis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	2	0

Abscess oral			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Abdominal infection			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	3 / 138 (2.17%)	7 / 692 (1.01%)	3 / 138 (2.17%)
occurrences (all)	3	7	3
Hyperkalaemia			
subjects affected / exposed	2 / 138 (1.45%)	6 / 692 (0.87%)	0 / 138 (0.00%)
occurrences (all)	3	8	0
Hypophosphataemia			
subjects affected / exposed	2 / 138 (1.45%)	7 / 692 (1.01%)	0 / 138 (0.00%)
occurrences (all)	2	9	0
Dyslipidaemia			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Hyponatraemia			
subjects affected / exposed	1 / 138 (0.72%)	4 / 692 (0.58%)	0 / 138 (0.00%)
occurrences (all)	1	5	0
Increased appetite			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Metabolic acidosis			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Vitamin D deficiency			
subjects affected / exposed	2 / 138 (1.45%)	4 / 692 (0.58%)	1 / 138 (0.72%)
occurrences (all)	2	4	1
Vitamin B12 deficiency			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Type 2 diabetes mellitus			

subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Tumour lysis syndrome			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Tetany			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Obesity			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	1 / 138 (0.72%)
occurrences (all)	1	2	1
Metabolic disorder			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	1 / 138 (0.72%)
occurrences (all)	0	1	1
Malnutrition			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Lactose intolerance			
subjects affected / exposed	2 / 138 (1.45%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	2	0
Iron deficiency			
subjects affected / exposed	1 / 138 (0.72%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	2	3	0
Hypovitaminosis			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hypouricaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hypoproteinaemia			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Hypophagia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hypomagnesaemia			

subjects affected / exposed	0 / 138 (0.00%)	6 / 692 (0.87%)	1 / 138 (0.72%)
occurrences (all)	0	9	1
Hypokalaemia			
subjects affected / exposed	7 / 138 (5.07%)	22 / 692 (3.18%)	1 / 138 (0.72%)
occurrences (all)	10	31	1
Hypoglycaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hypocalcaemia			
subjects affected / exposed	0 / 138 (0.00%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences (all)	0	7	0
Hypoalbminaemia			
subjects affected / exposed	0 / 138 (0.00%)	5 / 692 (0.72%)	0 / 138 (0.00%)
occurrences (all)	0	5	0
Hyperuricaemia			
subjects affected / exposed	6 / 138 (4.35%)	10 / 692 (1.45%)	3 / 138 (2.17%)
occurrences (all)	9	13	3
Hypertriglyceridaemia			
subjects affected / exposed	2 / 138 (1.45%)	3 / 692 (0.43%)	1 / 138 (0.72%)
occurrences (all)	2	3	1
Hyperphosphataemia			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Hypernatraemia			
subjects affected / exposed	0 / 138 (0.00%)	2 / 692 (0.29%)	0 / 138 (0.00%)
occurrences (all)	0	2	0
Hyperlipidaemia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	2 / 138 (1.45%)	8 / 692 (1.16%)	2 / 138 (1.45%)
occurrences (all)	5	11	2
Hypercholesterolaemia			
subjects affected / exposed	0 / 138 (0.00%)	4 / 692 (0.58%)	2 / 138 (1.45%)
occurrences (all)	0	4	2
Hypercalcaemia			

subjects affected / exposed	1 / 138 (0.72%)	6 / 692 (0.87%)	1 / 138 (0.72%)
occurrences (all)	1	6	1
Gout			
subjects affected / exposed	2 / 138 (1.45%)	6 / 692 (0.87%)	1 / 138 (0.72%)
occurrences (all)	2	6	1
Folate deficiency			
subjects affected / exposed	1 / 138 (0.72%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	1	1	0
Fluid retention			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Fluid overload			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0
Decreased appetite			
subjects affected / exposed	7 / 138 (5.07%)	48 / 692 (6.94%)	7 / 138 (5.07%)
occurrences (all)	9	56	9
Cachexia			
subjects affected / exposed	0 / 138 (0.00%)	1 / 692 (0.14%)	0 / 138 (0.00%)
occurrences (all)	0	1	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 July 2012	1. Eligibility criteria: - to clarify that study treatment was second-line therapy, subjects who only relapsed or been refractory to prior radiotherapy were eligible for the study; - subjects with SD were no longer considered eligible to enter Prolonged Maintenance (Maintenance II phase) as they were not expected to receive clinical benefit; - to make the pathological evaluation easier, other not further classified low malignant lymphoma by IHC was removed as part of the inclusion criteria; - subjects with documented Gilbert disease were allowed to be enrolled if total bilirubin was </= 3.0 x ULN. 2. Study Outcomes: - to differentiate overall survival as calculated from the beginning of Induction treatment with rituximab, to the overall survival calculated from the time of randomization to rituximab SC vs observation, overall survival was separated into OSregist (measured from the first Induction dose of rituximab) and OSrand (measured from the time of randomization); - to correct an error that partial response (PR) to complete response (CR) conversion rate was measured only at the end of Maintenance I; - to correct an error that the staging assessment done post-Maintenance I was compared with the subject's baseline status; - clarification that overall response rate was measured from the first dose of rituximab induction to the end of the Induction Phase; - response assessments were to be made according to the recommendations for Waldenstrom's macroglobulinemia; - the exploratory analysis was to be completed earlier to support submission; - for all secondary efficacy analyses, descriptive statistics and Kaplan-Meier curves were to be presented for non-randomized subjects and for the two randomized treatment groups.
26 July 2012	3. Study Assessments: - CT scans were done with contrast including neck to properly evaluate follicular lymphoma; - other diagnostic means were acceptable to properly evaluate gastric lymphoma; - Rituximab Administration Satisfaction Questionnaire (RASQ) replaced Cancer Therapy Satisfaction Questionnaire (CTSQ); - bone marrow assessments were required at baseline; - correction of Schedule of Assessments to include survival; - Off-Treatment Follow-Up added in the Schedule of Assessments. 4. Study Treatment: - the time window for the SC rituximab injection broadened to approximately 5 to 7 minutes; - SC rituximab not be withdrawn from the vial until the time of administration; - to follow normal medical practice on the observation period after SC rituximab injection; - IV rituximab dose could be round to the nearest 10 mg; - details of preparation and administration of SC rituximab and IV rituximab were removed from the protocol and provided in a separate Guidance Document; - the timing details of rituximab with respect to chemotherapy were clarified; - the dosages of prophylactic premedication are no longer specified; - only commercially available chemotherapy was allowed. 5. Study Design: - study timelines were modified for the enrollment period, the randomization period and for the total study duration; - the enrolment period was extended to 24 months; - the required number of events were adjusted for the log-rank test; - the definition of the end of study was revised. 6. Changes for Safety: - timing of SAE collection; - SAE reporting time frame to follow Sponsor's standard procedure; - clarification of SAE reporting requirements; - pregnancy was to be reported within 12 months after stopping study treatment; - Independent Data Monitoring Committee (IDMC) replaced the Data Safety Monitoring Board (DSMB); - interim safety analysis was added; - introducing the term "infusion/injection-related reactions". 7. Administrative changes

23 September 2012	- The sentence "or other not further classified low malignant lymphoma by immunohistochemistry" was consistently removed from the protocol v3.0; - "Infusion/injection-related reactions (IRRs)" was redefined as "infusion/administration-related reactions (IRRs/ARRs)"; - Clarification that the 1999 version of the International Working Group (Cheson) Criteria for Evaluation of Response in Non-Hodgkin's Lymphoma was to be used (which does not use PET), NOT the revised 2007 criteria; - More details were added to Appendix 2; Criteria for the Evaluation of Response in Waldenström's macroglobulinemia; - Specified that subjects in Arm A (Maintenance II) should continue treatment with rituximab SC until disease progression, unacceptable toxicity, withdrawal of subject consent or End of Study (EOS), whichever occurs first; - Permitted windows for delays in the administration of Treatment were included due to toxicity reasons; - Clarification about FLIPI as a standardized guide on prognosis of survival rates only for Follicular Lymphoma subjects; - Addition of the Cancer Therapy Satisfaction Questionnaire (CTSQ) as a tool for assessing subject preference; - After discontinuation of study treatment, subjects were to be followed-up until the end of the whole study for resolution of all SAEs related to rituximab maintenance therapy
06 July 2017	The AE and SAE reporting duration was clarified. Additional minor changes have been made to improve clarity and consistency: -The end of study section in the synopsis of protocol was revised to clarify that maintenance II arm B patients were expected to follow the same schedule of assessment as patients on arm A; - New medical contact and statistician names were added to the Protocol; - The number of subjects section was updated to reflect the final number of subjects randomized to maintenance II therapy and the enrolment time line; - Relevant sections were revised to remove the reference to stable disease at the end of maintenance I; - Clarification was added that the trial could be stopped if the 129th PFS event was reported; - In the relevant table the footnote link was corrected; - In the relevant section and table, clarification was added regarding the movement of subjects in to off-treatment follow-up following the end of treatment or their participation in maintenance II arm B; - In the relevant section, the guidance to record and assess the individual symptoms of infusion related reactions and administration related reactions was removed; - Spelling errors were corrected.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported